About Unravel Biosciences

Unravel Biosciences is a therapeutics company spun out from the Wyss Institute at Harvard University that accelerates target and drug discovery. rareSHIFT is a program that enables families and foundations to access Unravel’s unique platform for their own therapeutic discovery needs. Our AI-powered discovery engine uncovers new drug targets for complex disorders. Using existing, potentially repurposable drugs to understand the complex biology, we derisk drug discovery 2-3x faster and 10x cheaper than competing approaches. Not only that, but repurposed drugs may offer patients much faster therapeutic opportunities while new treatments are developed. Our proprietary drug discovery platform empowers us to identify and develop drugs capable of treating multiple diseases, alleviating the financial burden placed on any single rare disease population. This approach enables us to focus on diseases that are often overlooked by large biopharma companies due to their perceived high costs. Unravel is driven by and dedicated to patient well-being. By leveraging our platform technology, we can significantly reduce costs while extending our reach to help a greater number of patients. Connect with us to discuss how to develop therapeutics for your rare disease of interest.

• 2 Unravel-predicted drugs nominated for 4 clinical trials

  • Reached key clinic-ready milestone within 8-12 months of project start

  • Each led to novel drug target and therapeutic mechanism with cure-like efficacy for potentially more effective new drugs

• Multiple drugs rapidly tested off-label by patients with demonstrated efficacy using objective and subjective measures

• Drug response predictions validated clinically in oncology, infectious disease, and neurological disorders

  • Machine learned model outperformed all other stratification appraoches for oncology treatment response

  • Predicted risk of death outcome for specific statins in treating COVID-19 patients

  • Validated 6 predictions in mouse models

• Over a dozen foundation-sponsored therapeutics discovery programs in progress